Stock DPH DECHRA PHARMACEUTICALS
Add to a list
To use this feature you must be a member
Log inSign up

Financials Dechra Pharmaceuticals

Equities

DPH

GB0009633180

Market Closed - London S.E.
Other stock markets
 02:30:00 2024-01-16 am EST 		5-day change 1st Jan Change
3,866 GBX -.--% Intraday chart for Dechra Pharmaceuticals -.--% +0.21%
Apr. 11 Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million. CI
Apr. 09 Dechra Group Holdings Limited Appoints Paul Nicholas Sandland as Director CI

Valuation

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Capitalization 1 2,846 2,818 3,074 4,729 3,748 4,198
Enterprise Value (EV) 1 3,057 3,046 3,202 4,929 3,956 4,628
P/E ratio 75.1 x 91.3 x 86.9 x 85.6 x 64.8 x -150 x
Yield 0.92% 1.15% 1.2% 0.93% 1.3% 0.34%
Capitalization / Revenue 6.99 x 5.85 x 5.97 x 7.78 x 5.5 x 5.51 x
EV / Revenue 7.51 x 6.32 x 6.22 x 8.11 x 5.8 x 6.08 x
EV / EBITDA 43.9 x 42.5 x 37.9 x 40.1 x 29.2 x 74.4 x
EV / FCF 54 x 40.9 x 45 x -207 x 184 x -443 x
FCF Yield 1.85% 2.44% 2.22% -0.48% 0.54% -0.23%
Price to Book 5.64 x 5.54 x 4.82 x 7.47 x 5.62 x 5.56 x
Nbr of stocks (in thousands) 102,288 102,631 108,011 108,215 108,393 113,888
Reference price 2 27.82 27.46 28.46 43.70 34.58 36.86
Announcement Date 9/4/18 9/4/19 9/8/20 9/7/21 9/6/22 10/17/23
1GBP in Million2GBP
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net sales 1 407.1 481.8 515.1 608 681.8 761.5
EBITDA 1 69.6 71.6 84.5 123 135.6 62.2
EBIT 1 45.1 50.6 58.7 87 95.8 17.1
Operating Margin 11.08% 10.5% 11.4% 14.31% 14.05% 2.25%
Earnings before Tax (EBT) 1 28.9 27.8 40.9 74 77.6 -36.1
Net income 1 36.1 30.9 33.9 55.5 58.2 -27.9
Net margin 8.87% 6.41% 6.58% 9.13% 8.54% -3.66%
EPS 2 0.3704 0.3007 0.3276 0.5103 0.5340 -0.2459
Free Cash Flow 1 56.64 74.46 71.1 -23.82 21.48 -10.45
FCF margin 13.91% 15.46% 13.8% -3.92% 3.15% -1.37%
FCF Conversion (EBITDA) 81.38% 104% 84.14% - 15.84% -
FCF Conversion (Net income) 156.89% 240.98% 209.73% - 36.9% -
Dividend per Share 2 0.2550 0.3160 0.3429 0.4050 0.4489 0.1250
Announcement Date 9/4/18 9/4/19 9/8/20 9/7/21 9/6/22 10/17/23
1GBP in Million2GBP
Estimates

Balance Sheet Analysis

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net Debt 1 211 228 128 200 208 430
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 3.037 x 3.182 x 1.51 x 1.628 x 1.535 x 6.915 x
Free Cash Flow 1 56.6 74.5 71.1 -23.8 21.5 -10.5
ROE (net income / shareholders' equity) 8.94% 6.09% 5.91% 8.74% 8.96% -3.92%
ROA (Net income/ Total Assets) 3.41% 3.06% 3.22% 4.44% 4.78% 0.75%
Assets 1 1,060 1,009 1,053 1,251 1,219 -3,737
Book Value Per Share 2 4.940 4.960 5.900 5.850 6.150 6.630
Cash Flow per Share 2 0.7800 0.7800 2.110 1.090 1.120 0.6500
Capex 1 4.9 12 7.8 18.9 20.3 22.8
Capex / Sales 1.2% 2.49% 1.51% 3.11% 2.98% 2.99%
Announcement Date 9/4/18 9/4/19 9/8/20 9/7/21 9/6/22 10/17/23
1GBP in Million2GBP
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

  1. Stock Market
  2. Equities
  3. DPH Stock
  4. Financials Dechra Pharmaceuticals